GLP-1 and Peptide Provider Reviews

Provider directory

Operational standard

This policy is applied through a claim-level evidence ledger. Each material claim records the source, capture date, evidence class, reviewer and the pages that reuse it. Centralizing the record prevents a price or regulatory fact from being updated on one page while remaining stale elsewhere.

Pages are reviewed on a scheduled cadence and whenever a material trigger occurs: an FDA approval or warning, label change, new pivotal trial, shortage-status change, manufacturer pricing update, provider fee change, pharmacy disclosure change or substantiated correction. Cosmetic edits do not reset a clinical-review date.

Peptides Editorial distinguishes three forms of certainty. Verified means the current primary source directly supports the statement. Provider-reported means the company states the fact but additional facility, checkout or third-party confirmation may still be needed. Not normalized means the available evidence is insufficient for a comparative claim; the site does not fill the gap with an estimate.

Publication safeguards

• One visible H1 and one canonical URL per page.
• Answer-first summaries retain material qualifications, not just the favorable number.
• Medical efficacy is never inferred from a provider price, testimonial or receptor description.
• Compounded, investigational and FDA-approved products are labeled as different regulatory categories.
• Prices display the commitment, mandatory fees and evidence date in the same comparison context.
• Reviewer credentials and roles are stated narrowly; unsupported degrees, affiliations or licenses are not published.
• Corrections that alter rankings trigger recalculation across every dependent page.

Frequently asked questions